MedPath

Avatrombopag for the Treatment of Thrombocytopenia in Adults With Chronic Liver Disease Undergoing a Procedure

Terminated
Conditions
Thrombocytopenia
Registration Number
NCT03554759
Lead Sponsor
Sobi, Inc.
Brief Summary

Phase 4 observational cohort study to characterize the treatment patterns and effects of avatrombopag use in patients with thrombocytopenia associated with chronic liver disease who are either undergoing, or have already undergone, a procedure.

Detailed Description

Data (e.g. type of procedure, platelet count, etc.) will be collected retrospectively or prospectively from patient visits occurring within approximately 7 calendar days prior to the first dose of avatrombopag, on Procedure Day, on Discharge Day, and from any clinic visit performed up to 30 days post-procedure. All treatment decisions and clinical assessments will be at the discretion of the treating physician per routine medical care and are not mandated by study design or protocol.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Patient has thrombocytopenia associated with chronic liver disease and is planned for or underwent treatment with avatrombopag prior to a procedure
  • Patient provides written informed consent

Minimum Data for Retrospective Enrollment

  • Platelet count from approximately 7 days prior to starting avatrombopag
  • Platelet count on Procedure Day
Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in platelet countUp to 8 days after the last dose of avatrombopag.
Secondary Outcome Measures
NameTimeMethod
Proportion of patients who received a platelet transfusionFrom the first dose of avatrombopag to up to 15 days after the last dose of avatrombopag
Occurrence of adverse eventsFrom the first dose of avatrombopag to up to 30 days after the last dose of avatrombopag

Trial Locations

Locations (3)

Dova Site

🇺🇸

Philadelphia, Pennsylvania, United States

Dova Study Site

🇺🇸

Milwaukee, Wisconsin, United States

Dova Study SIte

🇺🇸

Roanoke, Virginia, United States

Dova Site
🇺🇸Philadelphia, Pennsylvania, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.